Tscan Therapeutics Inc (TCRX NASDAQ) stock market data APIs
$1.0748
0.04(3.7%)
as of December 5, 2025
Try our APIs with
free plan!
Tscan Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.0748
Open
1.1103
High
1.118
Low
1.0446
52 wk Range
0.91-4.8496
Market Cap
61 288 K
Shares Outstanding
52 471 K
Revenue
8 423 K
EPS
-0.28
Beta
1.03
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tscan Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tscan Therapeutics Inc data using free add-ons & libraries
Get Tscan Therapeutics Inc Fundamental Data
Tscan Therapeutics Inc Fundamental data includes:
- Net Revenue: 8 423 K
- EBITDA: -145 812 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.3367
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tscan Therapeutics Inc News
New
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up r...
TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week
(RTTNews) - TScan Therapeutics Inc. (TCRX), a clinical-stage biotechnology company, is set to host a virtual key opinion leader (KOL) event on December 8, 2025, at 8:00 a.m. ET. to discuss updates fro...
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cel...
After-Hours Biotech Rally: Clene Surges Ahead Of ALS Update; Werewolf, Biomea, Dyne Also Climb
(RTTNews) - Several biotech and therapeutics companies posted notable gains in after-hours trading on Tuesday, December 2, 2025, following a mix of corporate updates, investor anticipation, and recent...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
